MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2009.22.8585

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Bushnell David L, O'Dorisio Thomas M, O'Dorisio M Sue, Menda Yusuf, Hicks Rodney J, Van Cutsem Eric, Baulieu Jean-Louis, Borson-Chazot Francoise, Anthony Lowell, Benson Al B, Oberg Kjell, Grossman Ashley B, Connolly Mary, Bouterfa Hakim, Li Yong, Kacena Katherine A, LaFrance Norman, Pauwels Stanislas A

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors.

PATIENTS AND

METHODS

Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks.

RESULTS

Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.

CONCLUSION

(90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.

Для цитирования: Bushnell David L, O'Dorisio Thomas M, O'Dorisio M Sue, Menda Yusuf, Hicks Rodney J, Van Cutsem Eric, Baulieu Jean-Louis, Borson-Chazot Francoise, Anthony Lowell, Benson Al B, Oberg Kjell, Grossman Ashley B, Connolly Mary, Bouterfa Hakim, Li Yong, Kacena Katherine A, LaFrance Norman, Pauwels Stanislas A. 90Y-edotreotide for metastatic carcinoid refractory to octreotide.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. DOI: 10.1200/jco.2009.22.8585.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.